Antonella Tosco

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

The Role of ETI Therapy in Managing Sinusitis in Cystic Fibrosis pediatric population: A Study on Clinical Outcomes.

The Role of ETI Therapy in Managing Sinusitis in Cystic Fibrosis pediatric population: A Study on Clinical Outcomes.

Journal: Respiratory medicine

Published: January 16, 2026

Red blood cell deformability as a mechanobiological marker of CFTR dysfunction in cystic fibrosis.

Red blood cell deformability as a mechanobiological marker of CFTR dysfunction in cystic fibrosis.

Journal: iScience

Published: December 03, 2025

Peak nasal inspiratory flow as an adjunct measure of respiratory function in paediatric cystic fibrosis.

Peak nasal inspiratory flow as an adjunct measure of respiratory function in paediatric cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: June 01, 2025

Hemoglobin Levels in Children Treated for Cystic Fibrosis with CFTR Modulators: A Single Center Retrospective Study.

Hemoglobin Levels in Children Treated for Cystic Fibrosis with CFTR Modulators: A Single Center Retrospective Study.

Journal: Journal of clinical medicine

Published: March 08, 2025

Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction.

Blood platelet reduction after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis may depend on systemic inflammation reduction.

Journal: Scientific reports

Published: February 24, 2025

TAS2R38 genotype and CRS severity in children with cystic fibrosis.

TAS2R38 genotype and CRS severity in children with cystic fibrosis.

Journal: Heliyon

Published: December 31, 2024

Tracheal Diverticula in People with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: An Italian Multicenter Retrospective Study.

Tracheal Diverticula in People with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: An Italian Multicenter Retrospective Study.

Journal: Journal of clinical medicine

Published: November 27, 2024

The treatment with Elexacaftor/Tezacaftor/Ivacaftor significantly increases serum bilirubin and decreases blood platelets in children and adolescents with cystic fibrosis homozygous or double heterozygous for the F508del CFTR variant.

The treatment with Elexacaftor/Tezacaftor/Ivacaftor significantly increases serum bilirubin and decreases blood platelets in children and adolescents with cystic fibrosis homozygous or double heterozygous for the F508del CFTR variant.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: October 25, 2024

Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in a Cystic Fibrosis Child With L1077P Mutation.

Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in a Cystic Fibrosis Child With L1077P Mutation.

Journal: Pediatric pulmonology

Published: October 17, 2024

A Longitudinal Study of Glucose Tolerance in Cystic Fibrosis: The Central Role of Beta Cell Functional Mass.

A Longitudinal Study of Glucose Tolerance in Cystic Fibrosis: The Central Role of Beta Cell Functional Mass.

Journal: The Journal of clinical endocrinology and metabolism

Published: August 24, 2023

Pseudo-Bartter syndrome in infant with cystic fibrosis screen positive, inconclusive diagnosis: A case report.

Pseudo-Bartter syndrome in infant with cystic fibrosis screen positive, inconclusive diagnosis: A case report.

Journal: Clinical case reports

Published: July 04, 2023

Primary ciliary dyskinesia treatment: time for a new approach?

Primary ciliary dyskinesia treatment: time for a new approach?

Journal: The Lancet. Respiratory medicine

Published: June 14, 2023

Showing 1-12 of 48

Last Updated: 09/26/2026